Blood test for diagnosis of cancer cachexia

Comparison of Il-6 and CRP levels in patients with non-small cell Lung cancer, ovarian cancer, colon cancer or cervical cancer with or without cachexia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12615000193572

Enrollment

357

Registered

2015-02-27

Start date

2015-02-02

Completion date

2016-02-25

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Case Control study conducted at the National Cancer Institute, Cairo University, Egypt. The de-identified data was then used by Deakin University for secondary analysis to determine if IL-6 and or CRP could be used as a predictive biomarker for the likely onset of cachexia.

Interventions

We will take blood samples from both the cases and controls during their check-up. We will use ELISA Kits to measure IL-6 and CRP in each case and controls. Then we will get the results from both the cases and controls and compare it. The blood sample will be taken once only.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

Cases, from cachexia clinic at the national Cancer Institute, Cairo University who have cancer cachexia related to underlying non-small cell lung cancer, colon cancer, ovarian cancer or cervical cancer. Controls patients from the oncology clinic who have the same type of cancer but who do not have cachexia. The primary diagnosis of the controls should be less than or within 6 months. All the patients should have a biopsy proven the diagnosis of cancer. Non of the patients will have an inflammatory diseases other than cancer or cancer cachexia.

Exclusion criteria

The primary diagnosis of the controls less than or within 6 months from the diagnosis.

Outcome results